$36.99
0.62%
Nasdaq, Aug 29, 10:07 pm CET
ISIN
US04963C2098
Symbol
ATRC

AtriCure, Inc. Stock price

$36.99
+5.26 16.58% 1M
-1.75 4.52% 6M
+6.43 21.04% YTD
+11.17 43.26% 1Y
-8.87 19.34% 3Y
-7.74 17.30% 5Y
+12.53 51.23% 10Y
+23.39 171.99% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.23 0.62%

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$1.8b
Net debt
positive
Cash
$117.8m
Shares outstanding
49.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.7 | 3.4
EV/Sales
3.6 | 3.3
EV/FCF
216.0
P/B
4.0
Financial Health
Equity Ratio
75.7%
Return on Equity
-9.7%
ROCE
-6.3%
ROIC
-8.9%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$500.0m | $541.3m
EBITDA
$-31.0m | $51.7m
EBIT
$-34.1m | $-20.5m
Net Income
$-36.4m | $-22.4m
Free Cash Flow
$8.3m
Growth (TTM | estimate)
Revenue
16.3% | 16.3%
EBITDA
2.8% | 239.8%
EBIT
2.2% | 48.7%
Net Income
9.5% | 50.0%
Free Cash Flow
142.2%
Margin (TTM | estimate)
Gross
74.7%
EBITDA
-6.2% | 9.6%
EBIT
-6.8%
Net
-7.3% | -4.1%
Free Cash Flow
1.7%
More
EPS
$-0.8
FCF per Share
$0.2
Short interest
4.1%
Employees
1k
Rev per Employee
$360.0k
Show more

Is AtriCure, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

AtriCure, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a AtriCure, Inc. forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a AtriCure, Inc. forecast:

Buy
93%
Hold
7%

Financial data from AtriCure, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
500 500
16% 16%
100%
- Direct Costs 126 126
17% 17%
25%
374 374
16% 16%
75%
- Selling and Administrative Expenses 299 299
10% 10%
60%
- Research and Development Expense 105 105
31% 31%
21%
-31 -31
3% 3%
-6%
- Depreciation and Amortization 3.04 3.04
3% 3%
1%
EBIT (Operating Income) EBIT -34 -34
2% 2%
-7%
Net Profit -36 -36
9% 9%
-7%

In millions USD.

Don't miss a Thing! We will send you all news about AtriCure, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AtriCure, Inc. Stock News

Neutral
Business Wire
13 days ago
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2025 Wells Fargo Healthcare Conference. AtriCure's management is scheduled to participate in a fires...
Positive
The Motley Fool
about one month ago
AtriCure (ATRC) Q2 Revenue Jumps 17%
Neutral
Seeking Alpha
about one month ago
AtriCure, Inc. (NASDAQ:ATRC ) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Angela L. Wirick - Chief Financial Officer Michael H.
More AtriCure, Inc. News

Company Profile

AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.

Head office United States
CEO Michael Carrel
Employees 1,300
Founded 1994
Website www.atricure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today